↓ Skip to main content

Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients

Overview of attention for article published in Oncotarget, August 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#27 of 12,011)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
45 news outlets
reddit
1 Redditor

Citations

dimensions_citation
15 Dimensions

Readers on

mendeley
16 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients
Published in
Oncotarget, August 2017
DOI 10.18632/oncotarget.19925
Pubmed ID
Authors

Lijun Dong, Dan Lei, Haijun Zhang

Abstract

Epidermal growth factor receptor (EGFR) mutations (EGFRm(+)) occur in 10-35% of non-small-cell lung cancer (NSCLC) cases and confer sensitivity to EGFR tyrosine kinase inhibitors (TKIs). EGFR TKIs are standard treatments for NSCLC patients harboring EGFR exon 19 deletions or exon 21 L858R point mutations. Despite initial benefit, most patients develop drug resistance, posing a challenge to oncologists. The secondary T790M point mutation in EGFR exon 20 contributes to approximately 60% of resistance cases. Optimum strategies for overcoming acquired EGFR TKI resistance are not clearly defined, although current common practice is to switch to platinum-based chemotherapy following resistance onset. While the second-generation EGFR TKIs, including afatinib, dacomitinib, and neratinib, exhibit promising preclinical activity against T790M mutants, dose-limiting toxicities in patients have limited clinical success. However, third generation EGFR TKIs appear able to overcome this mutation. Other treatment options aimed at EGFR TKI resistance include use of an EGFR TKI beyond progression, and chemotherapy plus an EGFR TKI. This review focuses on improved anticancer agents and therapy options for NSCLC patients with acquired EGFR TKI resistance.

Mendeley readers

The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 16 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 4 25%
Researcher 2 13%
Student > Bachelor 2 13%
Other 2 13%
Student > Ph. D. Student 2 13%
Other 3 19%
Unknown 1 6%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 4 25%
Pharmacology, Toxicology and Pharmaceutical Science 3 19%
Medicine and Dentistry 3 19%
Agricultural and Biological Sciences 1 6%
Social Sciences 1 6%
Other 3 19%
Unknown 1 6%

Attention Score in Context

This research output has an Altmetric Attention Score of 355. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 July 2018.
All research outputs
#30,150
of 13,216,344 outputs
Outputs from Oncotarget
#27
of 12,011 outputs
Outputs of similar age
#1,513
of 273,614 outputs
Outputs of similar age from Oncotarget
#4
of 845 outputs
Altmetric has tracked 13,216,344 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,011 research outputs from this source. They receive a mean Attention Score of 3.8. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 273,614 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 845 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.